The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Plasma Protease C1-inhibitor Treatment-Global Market Insights and Sales Trends 2025
Synopsis
This report on the plasma protease C1-inhibitors treatment market analyzes the current and future scenario of the global market. Large number of acute HAE patients is increasing the usage of plasma protease C1-inhibitors treatment. Increasing prevalence of rare diseases around the world, promising pipeline drugs and novel therapies, rising investments in innovation of inhibitor drugs and increasing HAE awareness programs are the major drivers of the global plasma protease C1-inhibitors treatment market.
The global Plasma Protease C1-inhibitor Treatment market size is expected to reach US$ 9897.1 million by 2029, growing at a CAGR of 17.3% from 2023 to 2029. The market is mainly driven by the significant applications of Plasma Protease C1-inhibitor Treatment in various end use industries. The expanding demands from the Hospital Pharmacies and Independent Pharmacies and Outlets, are propelling Plasma Protease C1-inhibitor Treatment market. C1-inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Kallikrein Inhibitor (Kalbitor) segment is estimated at % CAGR for the next seven-year period.
Based on drug class, the market has been segmented into C1-inhibitors (C1-esterase Inhibitor, Recombinant Inhibitor); Kallikrein Inhibitor (Kalbitor); Selective Bradykinin B2 Receptor Antagonist (Firazyr). The drug class market segments have been analyzed based on available approved products, cost-effectiveness, and preference given by the physicians for the treatment of HAE patients.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Plasma Protease C1-inhibitor Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Plasma Protease C1-inhibitor Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Plasma Protease C1-inhibitor Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Plasma Protease C1-inhibitor Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Plasma Protease C1-inhibitor Treatment covered in this report include Takeda, CSL, Sanquin and Pharming Group, etc.
The global Plasma Protease C1-inhibitor Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Takeda
CSL
Sanquin
Pharming Group
Global Plasma Protease C1-inhibitor Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Plasma Protease C1-inhibitor Treatment market, Segment by Type:
C1-inhibitors
Kallikrein Inhibitor (Kalbitor)
Global Plasma Protease C1-inhibitor Treatment market, by Application
Hospital Pharmacies
Independent Pharmacies and Outlets
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Plasma Protease C1-inhibitor Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
This report on the plasma protease C1-inhibitors treatment market analyzes the current and future scenario of the global market. Large number of acute HAE patients is increasing the usage of plasma protease C1-inhibitors treatment. Increasing prevalence of rare diseases around the world, promising pipeline drugs and novel therapies, rising investments in innovation of inhibitor drugs and increasing HAE awareness programs are the major drivers of the global plasma protease C1-inhibitors treatment market.
The global Plasma Protease C1-inhibitor Treatment market size is expected to reach US$ 9897.1 million by 2029, growing at a CAGR of 17.3% from 2023 to 2029. The market is mainly driven by the significant applications of Plasma Protease C1-inhibitor Treatment in various end use industries. The expanding demands from the Hospital Pharmacies and Independent Pharmacies and Outlets, are propelling Plasma Protease C1-inhibitor Treatment market. C1-inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Kallikrein Inhibitor (Kalbitor) segment is estimated at % CAGR for the next seven-year period.
Based on drug class, the market has been segmented into C1-inhibitors (C1-esterase Inhibitor, Recombinant Inhibitor); Kallikrein Inhibitor (Kalbitor); Selective Bradykinin B2 Receptor Antagonist (Firazyr). The drug class market segments have been analyzed based on available approved products, cost-effectiveness, and preference given by the physicians for the treatment of HAE patients.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Plasma Protease C1-inhibitor Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Plasma Protease C1-inhibitor Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Plasma Protease C1-inhibitor Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Plasma Protease C1-inhibitor Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Plasma Protease C1-inhibitor Treatment covered in this report include Takeda, CSL, Sanquin and Pharming Group, etc.
The global Plasma Protease C1-inhibitor Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Takeda
CSL
Sanquin
Pharming Group
Global Plasma Protease C1-inhibitor Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Plasma Protease C1-inhibitor Treatment market, Segment by Type:
C1-inhibitors
Kallikrein Inhibitor (Kalbitor)
Global Plasma Protease C1-inhibitor Treatment market, by Application
Hospital Pharmacies
Independent Pharmacies and Outlets
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Plasma Protease C1-inhibitor Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Plasma Protease C1-inhibitor Treatment
1.1 Plasma Protease C1-inhibitor Treatment Market Overview
1.1.1 Plasma Protease C1-inhibitor Treatment Product Scope
1.1.2 Plasma Protease C1-inhibitor Treatment Market Status and Outlook
1.2 Global Plasma Protease C1-inhibitor Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Plasma Protease C1-inhibitor Treatment Market Size by Region (2018-2029)
1.4 Global Plasma Protease C1-inhibitor Treatment Historic Market Size by Region (2018-2023)
1.5 Global Plasma Protease C1-inhibitor Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Plasma Protease C1-inhibitor Treatment Market Size (2018-2029)
1.6.1 North America Plasma Protease C1-inhibitor Treatment Market Size (2018-2029)
1.6.2 Europe Plasma Protease C1-inhibitor Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Plasma Protease C1-inhibitor Treatment Market Size (2018-2029)
1.6.4 Latin America Plasma Protease C1-inhibitor Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Size (2018-2029)
2 Plasma Protease C1-inhibitor Treatment Market by Type
2.1 Introduction
2.1.1 C1-inhibitors
2.1.2 Kallikrein Inhibitor (Kalbitor)
2.2 Global Plasma Protease C1-inhibitor Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Plasma Protease C1-inhibitor Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Plasma Protease C1-inhibitor Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Plasma Protease C1-inhibitor Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Plasma Protease C1-inhibitor Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Plasma Protease C1-inhibitor Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Plasma Protease C1-inhibitor Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Plasma Protease C1-inhibitor Treatment Revenue Breakdown by Type (2018-2029)
3 Plasma Protease C1-inhibitor Treatment Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacies
3.1.2 Independent Pharmacies and Outlets
3.2 Global Plasma Protease C1-inhibitor Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Plasma Protease C1-inhibitor Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Plasma Protease C1-inhibitor Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Plasma Protease C1-inhibitor Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Plasma Protease C1-inhibitor Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Plasma Protease C1-inhibitor Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Plasma Protease C1-inhibitor Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Plasma Protease C1-inhibitor Treatment Revenue Breakdown by Application (2018-2029)
4 Plasma Protease C1-inhibitor Treatment Competition Analysis by Players
4.1 Global Plasma Protease C1-inhibitor Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Plasma Protease C1-inhibitor Treatment as of 2022)
4.3 Date of Key Players Enter into Plasma Protease C1-inhibitor Treatment Market
4.4 Global Top Players Plasma Protease C1-inhibitor Treatment Headquarters and Area Served
4.5 Key Players Plasma Protease C1-inhibitor Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Plasma Protease C1-inhibitor Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Takeda
5.1.1 Takeda Profile
5.1.2 Takeda Main Business
5.1.3 Takeda Plasma Protease C1-inhibitor Treatment Products, Services and Solutions
5.1.4 Takeda Plasma Protease C1-inhibitor Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 Takeda Recent Developments
5.2 CSL
5.2.1 CSL Profile
5.2.2 CSL Main Business
5.2.3 CSL Plasma Protease C1-inhibitor Treatment Products, Services and Solutions
5.2.4 CSL Plasma Protease C1-inhibitor Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 CSL Recent Developments
5.3 Sanquin
5.3.1 Sanquin Profile
5.3.2 Sanquin Main Business
5.3.3 Sanquin Plasma Protease C1-inhibitor Treatment Products, Services and Solutions
5.3.4 Sanquin Plasma Protease C1-inhibitor Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Pharming Group Recent Developments
5.4 Pharming Group
5.4.1 Pharming Group Profile
5.4.2 Pharming Group Main Business
5.4.3 Pharming Group Plasma Protease C1-inhibitor Treatment Products, Services and Solutions
5.4.4 Pharming Group Plasma Protease C1-inhibitor Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Pharming Group Recent Developments
6 North America
6.1 North America Plasma Protease C1-inhibitor Treatment Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Plasma Protease C1-inhibitor Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Plasma Protease C1-inhibitor Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Plasma Protease C1-inhibitor Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Plasma Protease C1-inhibitor Treatment Market Dynamics
11.1 Plasma Protease C1-inhibitor Treatment Industry Trends
11.2 Plasma Protease C1-inhibitor Treatment Market Drivers
11.3 Plasma Protease C1-inhibitor Treatment Market Challenges
11.4 Plasma Protease C1-inhibitor Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
